ODN 2336 is a A-Class CpG ODN (oligodeoxynucleotides), is a potent IL-18 mRNA. ODN 2336 can be used as adjuvant of vaccines[1][2][3].
ODN 2336 (0.5 µM; 24, 48 h) up-regulates the expression of f CD69 and IFN-α[1].
ODN 2336 (3 µg/ml; 4 h) stimulates strang transcription of IP-10 mRNA after 4 h in human PBMC[1].
ODN 2336 (3 µg/ml; 2, 4, 16 h) up-regulates the expression of IL-18 mRNA at the 16 htime point[1].
ODN 2336 (50 μg/mL; 20 h) with IL-3 (10 ng/mL) induces the production of IFN-α in the plasma of adult and cord blood[2].
ODN 2336 (0.3125-5 µg/ml; 24 h) increases the production of FNA1 in a dose-dependent manner in human PBMCs[3].
[1]. urk M, et al. C-Class CpG ODN: sequence requirements and characterization of immunostimulatory activities on mRNA level. Immunobiology. 2004;209(1-2):141-54.
[2]. old MC, et al. Purified neonatal plasmacytoid dendritic cells overcome intrinsic maturation defect with TLR agonist stimulation. Pediatr Res. 2006 Jul;60(1):34-7.
[3]. Hilbert T, et al. Beta2-adrenoceptor stimulation suppresses TLR9-dependent IFNA1 secretion in human peripheral blood mononuclear cells. PLoS One. 2013 May 28;8(5):e65024.